The global oral cancer treatment market was valued at $ 1,710.53 million 2020, and is projected to reach $ 2,729.72 Million by 2030 registering a CAGR of 4.80% from 2021 to 2030.
Oral cancer is a type of head and neck cancer that manifests itself in the mouth as a tumor. The tongue, lips, cheeks, gums, tonsils, and salivary glands are the most common sites for oral or mouth cancer. Oral cancers are classified as either benign or malignant. Surgical removal of benign tumors is possible. Squamous cell carcinoma accounts for 90% of malignant oral malignancies, which can spread to other parts of the body. Furthermore, according to the Oral Cancer Foundation, every year around 53,000 new oral cancer cases are diagnosed and more than 9,750 people succumb to the disease in the U.S. Oral cancer accounts for 4% of total cancer cases and causes 2.2% deaths in the U.S. In western countries, prevalence of oral cancer is 2% to 6% of the total cancer cases. In addition, in Asia-Pacific, the oropharyngeal cancer is more common among men than women. According to the National Cancer Institute, 60% of people with oral cancer survive for five years or more and 70% to 90% of people with Stage 1 or 2 cancer survive for more than 5 years.
The growth of the global oral cancer treatment market is majorly driven by rise in prevalence of oral or mouth cancer globally is a major factor fostering the growth of the market. Rise in expenditure on the development of healthcare infrastructure, increase in consumption of tobacco products such as cigarettes, cigars, pipes and chewing tobacco and upsurge in the special designation from regulatory authorities are other factors also fostering the growth of the market. Increase in personal disposable income coupled with rise in prevalence of papillomavirus infection is other indirect determinant that will create lucrative market growth opportunities.
However, lack of awareness about the oral cancer in the backward and underdeveloped areas will hamper the market growth. Risk of recurrence even after the treatment will also hamper the market growth rate.
The oral cancer treatment market is segmented on the basis of treatment, age group, end user, and region. Depending on treatment, the market is classified into chemotherapy, immunotherapy, targeted therapy. The age group segment is further categorized into 30-49, 50-69 and 70<. By end user, it is fragmented into hospital pharmacies, drug stores & retail pharmacies, online stores. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Oral cancer is a type of head and neck cancer that manifests itself in the mouth as a tumor. The tongue, lips, cheeks, gums, tonsils, and salivary glands are the most common sites for oral or mouth cancer. Oral cancers are classified as either benign or malignant. Surgical removal of benign tumors is possible. Squamous cell carcinoma accounts for 90% of malignant oral malignancies, which can spread to other parts of the body. Furthermore, according to the Oral Cancer Foundation, every year around 53,000 new oral cancer cases are diagnosed and more than 9,750 people succumb to the disease in the U.S. Oral cancer accounts for 4% of total cancer cases and causes 2.2% deaths in the U.S. In western countries, prevalence of oral cancer is 2% to 6% of the total cancer cases. In addition, in Asia-Pacific, the oropharyngeal cancer is more common among men than women. According to the National Cancer Institute, 60% of people with oral cancer survive for five years or more and 70% to 90% of people with Stage 1 or 2 cancer survive for more than 5 years.
The growth of the global oral cancer treatment market is majorly driven by rise in prevalence of oral or mouth cancer globally is a major factor fostering the growth of the market. Rise in expenditure on the development of healthcare infrastructure, increase in consumption of tobacco products such as cigarettes, cigars, pipes and chewing tobacco and upsurge in the special designation from regulatory authorities are other factors also fostering the growth of the market. Increase in personal disposable income coupled with rise in prevalence of papillomavirus infection is other indirect determinant that will create lucrative market growth opportunities.
However, lack of awareness about the oral cancer in the backward and underdeveloped areas will hamper the market growth. Risk of recurrence even after the treatment will also hamper the market growth rate.
The oral cancer treatment market is segmented on the basis of treatment, age group, end user, and region. Depending on treatment, the market is classified into chemotherapy, immunotherapy, targeted therapy. The age group segment is further categorized into 30-49, 50-69 and 70<. By end user, it is fragmented into hospital pharmacies, drug stores & retail pharmacies, online stores. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
- The study provides an in-depth analysis of the global oral cancer treatment market along with the current trends and future estimations to elucidate the imminent investment pockets.
- A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
- Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
- Extensive analysis of the key segments of the industry helps understand the applications and products of oral injury used across the globe.
- Key market players and their strategies have been analyzed to understand the competitive outlook of the market.
KEY MARKET SEGMENTS
By Treatment
- Chemotherapy
- Immunotherapy
- Targeted Therapy
- By Age Group
- 30-49
- 50-69
- 70<
By End User
- Hospital Pharmacies
- Drug Stores & Retail Pharmacies
- Online Stores
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Porter’s five force analysis
3.4. Top player positioning, 2020
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Rise in prevalence of oral cancer
3.5.1.2. Surge in global geriatric population
3.5.1.3. Increase in government expenditure on healthcare
3.5.2. Restraint
3.5.2.1. Adverse effects associated with the use cancer drugs
3.5.3. Opportunities
3.5.3.1. High growth potential in untapped emerging economies
3.5.3.2. Increase in number of pipeline drugs
3.5.4. Impact analysis
3.6. COVID-19 impact analysis on the oral cancer treatment market
CHAPTER 4: ORAL CANCER TREATMENT MARKET, BY DRUG TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Chemotherapy
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Immunotherapy
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. Targeted therapy
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
CHAPTER 5: ORAL CANCER TREATMENT MARKET, BY AGE GROUP
5.1. Overview
5.1.1. Market size and forecast
5.2.30-49
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3.50-69
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4.70< 5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
CHAPTER 6: ORAL CANCER TREATMENT MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital Pharmacies
6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country
6.3. Drug Stores & Retail Pharmacies
6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country
6.4. Online Stores
6.4.1. Market size and forecast, by region
6.4.2. Market analysis, by country
CHAPTER 7: ORAL CANCER TREATMENT MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends, growth factors, and opportunities
7.2.2. Market size and forecast, by country
7.2.2.1. U.S. oral cancer treatment market, by drug type
7.2.2.2. U.S. oral cancer treatment market, by age group
7.2.2.3. U.S. oral cancer treatment market, by distribution channel
7.2.2.4. Canada oral cancer treatment market, by drug type
7.2.2.5. Canada oral cancer treatment market, by age group
7.2.2.6. Canada oral cancer treatment market, by distribution channel
7.2.2.7. Mexico oral cancer treatment market, by drug type
7.2.2.8. Mexico oral cancer treatment market, by age group
7.2.2.9. Mexico oral cancer treatment market, by distribution channel
7.3. Europe
7.3.1. Key market trends, growth factors, and opportunities
7.3.2. Market size and forecast, by country
7.3.2.1. Germany oral cancer treatment market, by drug type
7.3.2.2. Germany oral cancer treatment market, by age group
7.3.2.3. Germany oral cancer treatment market, by distribution channel
7.3.2.4. France oral cancer treatment market, by drug type
7.3.2.5. France oral cancer treatment market, by age group
7.3.2.6. France oral cancer treatment market, by distribution channel
7.3.2.7. UK oral cancer treatment market, by drug type
7.3.2.8. UK oral cancer treatment market, by age group
7.3.2.9. UK oral cancer treatment market, by distribution channel
7.3.2.10. Italy oral cancer treatment market, by drug type
7.3.2.11. Italy oral cancer treatment market, by age group
7.3.2.12. Italy oral cancer treatment market, by distribution channel
7.3.2.13. Spain oral cancer treatment market, by drug type
7.3.2.14. Spain oral cancer treatment market, by age group
7.3.2.15. Spain oral cancer treatment market, by distribution channel
7.3.2.16. Rest of Europe oral cancer treatment market, by drug type
7.3.2.17. Rest of Europe oral cancer treatment market, by age group
7.3.2.18. Rest of Europe oral cancer treatment market, by distribution channel
7.3.3. Europe oral cancer treatment market, by drug type
7.3.4. Europe oral cancer treatment market, by age group
7.3.5. Europe oral cancer treatment market, by distribution channel
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors, and opportunities
7.4.2. Market size and forecast, by country
7.4.2.1. Japan oral cancer treatment market, by drug type
7.4.2.2. Japan oral cancer treatment market, by age group
7.4.2.3. Japan oral cancer treatment market, by distribution channel
7.4.2.4. China oral cancer treatment market, by drug type
7.4.2.5. China oral cancer treatment market, by age group
7.4.2.6. China oral cancer treatment market, by distribution channel
7.4.2.7. Australia oral cancer treatment market, by drug type
7.4.2.8. Australia oral cancer treatment market, by age group
7.4.2.9. Australia oral cancer treatment market, by distribution channel
7.4.2.10. India oral cancer treatment market, by drug type
7.4.2.11. India oral cancer treatment market, by age group
7.4.2.12. India oral cancer treatment market, by distribution channel
7.4.2.13. South Korea oral cancer treatment market, by drug type
7.4.2.14. South Korea oral cancer treatment market, by age group
7.4.2.15. South Korea oral cancer treatment market, by distribution channel
7.4.2.16. Rest of Asia-Pacific oral cancer treatment market, by drug type
7.4.2.17. Rest of Asia-Pacific oral cancer treatment market, by age group
7.4.2.18. Rest of Asia-Pacific oral cancer treatment market, by distribution channel
7.4.3. Asia-Pacific oral cancer treatment market, by drug type
7.4.4. Asia-Pacific oral cancer treatment market, by age group
7.4.5. Asia-Pacific oral cancer treatment market, by distribution channel
7.5. LAMEA
7.5.1. Key market trends, growth factors, and opportunities
7.5.2. Market size and forecast, by country
7.5.2.1. Brazil oral cancer treatment market, by drug type
7.5.2.2. Brazil oral cancer treatment market, by age group
7.5.2.3. Brazil oral cancer treatment market, by distribution channel
7.5.2.4. Saudi Arabia oral cancer treatment market, by drug type
7.5.2.5. Saudi Arabia oral cancer treatment market, by age group
7.5.2.6. Saudi Arabia oral cancer treatment market, by distribution channel
7.5.2.7. South Africa oral cancer treatment market, by drug type
7.5.2.8. South Africa oral cancer treatment market, by age group
7.5.2.9. South Africa oral cancer treatment market, by distribution channel
7.5.2.10. Rest of LAMEA oral cancer treatment market, by drug type
7.5.2.11. Rest of LAMEA oral cancer treatment market, by age group
7.5.2.12. Rest of LAMEA oral cancer treatment market, by distribution channel
7.5.3. LAMEA oral cancer treatment market, by drug type
7.5.4. LAMEA oral cancer treatment market, by age group
7.5.5. LAMEA oral cancer treatment market, by distribution channel
CHAPTER 8: COMPANY PROFILES
8.1. BRISTOL MAYERS SQUIBB COMPANY
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments
8.2. CIPLA INC.
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments
8.3. ELI-LILLY
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.4. F-HOFFMANN-LA-ROCHE
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.4.6. Key strategic moves and developments
8.5. FRESENIUS KABI AG
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.6. INTAS PHARMACEUTICALS LTD.
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Product portfolio
8.7. MERCK & CO. INC.
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.7.6. Key strategic moves and developments
8.8. SANOFI S.A
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.8.6. Key strategic moves and developments
8.9. TEVA PHARMACEUTICALS INDUSTRIES LTD
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product Portfolio
8.9.5. Business performance
8.10. VIATRIS INC. (MYLAN N.V)
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product Portfolio
8.10.5. Business performance
List of Tables
TABLE 01. ORAL CANCER TREATMENT MARKET, BY DRUG TYPE, 2020-2030 ($MILLION)
TABLE 02. CHEMOTHERAPY ORAL CANCER TREATMENT MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 03. IMMUNOTHERAPY ORAL CANCER TREATMENT MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 04. TARGETED THERAPY ORAL CANCER TREATMENT MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 05. ORAL CANCER TREATMENT MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
TABLE 06.30-49 ORAL CANCER TREATMENT MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 07.50-69 CANCER TREATMENT MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 08.70< CANCER TREATMENT MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 09. ORAL CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
TABLE 10. ORAL CANCER TREATMENT MARKET FOR HOSPITALS PHARMACIES, BY REGION, 2020-2030 ($MILLION)
TABLE 11. ORAL CANCER TREATMENT MARKET FOR DRUG STORES & RETAIL PHARMACIES, BY REGION, 2020-2030 ($MILLION)
TABLE 12. ORAL CANCER TREATMENT MARKET FOR ONLINE STORES, BY REGION, 2020-2030 ($MILLION)
TABLE 13. ORAL CANCER TREATMENT MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 14. NORTH AMERICA ORAL CANCER TREATMENT MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 15. U.S. ORAL CANCER TREATMENT MARKET, BY DRUG TYPE, 2020-2030
TABLE 16. U.S. ORAL CANCER TREATMENT MARKET, BY AGE GROUP, 2020-2030
TABLE 17. U.S. ORAL CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 18. CANADA ORAL CANCER TREATMENT MARKET, BY DRUG TYPE, 2020-2030
TABLE 19. CANADA ORAL CANCER TREATMENT MARKET, BY AGE GROUP, 2020-2030
TABLE 20. CANADA ORAL CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 21. MEXICO ORAL CANCER TREATMENT MARKET, BY DRUG TYPE, 2020-2030
TABLE 22. MEXICO ORAL CANCER TREATMENT MARKET, BY AGE GROUP, 2020-2030
TABLE 23. MEXICO ORAL CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 24. EUROPE ORAL CANCER TREATMENT MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 25. GERMANY ORAL CANCER TREATMENT MARKET, BY DRUG TYPE, 2020-2030
TABLE 26. GERMANY ORAL CANCER TREATMENT MARKET, BY AGE GROUP, 2020-2030
TABLE 27. GERMANY ORAL CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 28. FRANCE ORAL CANCER TREATMENT MARKET, BY DRUG TYPE, 2020-2030
TABLE 29. FRANCE ORAL CANCER TREATMENT MARKET, BY AGE GROUP, 2020-2030
TABLE 30. FRANCE ORAL CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 31. UK ORAL CANCER TREATMENT MARKET, BY DRUG TYPE, 2020-2030
TABLE 32. UKORAL CANCER TREATMENT MARKET, BY AGE GROUP, 2020-2030
TABLE 33. UK ORAL CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 34. ITALY ORAL CANCER TREATMENT MARKET, BY DRUG TYPE, 2020-2030
TABLE 35. ITALY ORAL CANCER TREATMENT MARKET, BY AGE GROUP, 2020-2030
TABLE 36. ITALY ORAL CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 37. SPAIN ORAL CANCER TREATMENT MARKET, BY DRUG TYPE, 2020-2030
TABLE 38. SPAIN ORAL CANCER TREATMENT MARKET, BY AGE GROUP, 2020-2030
TABLE 39. SPAIN ORAL CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 40. REST OF EUROPE ORAL CANCER TREATMENT MARKET, BY DRUG TYPE, 2020-2030
TABLE 41. REST OF EUROPE ORAL CANCER TREATMENT MARKET, BY AGE GROUP, 2020-2030
TABLE 42. REST OF EUROPE ORAL CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 43. EUROPE ORAL CANCER TREATMENT MARKET, BY DRUG TYPE, 2020-2030
TABLE 44. EUROPE ORAL CANCER TREATMENT MARKET, BY AGE GROUP, 2020-2030
TABLE 45. EUROPE ORAL CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 46. ASIA-PACIFIC ORAL CANCER TREATMENT MARKET, BY COUNTRY, 2020-2030($MILLION)
TABLE 47. JAPAN ORAL CANCER TREATMENT MARKET, BY DRUG TYPE, 2020-2030
TABLE 48. JAPAN ORAL CANCER TREATMENT MARKET, BY AGE GROUP, 2020-2030
TABLE 49. JAPAN ORAL CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 50. CHINA ORAL CANCER TREATMENT MARKET, BY DRUG TYPE, 2020-2030
TABLE 51. CHINA ORAL CANCER TREATMENT MARKET, BY AGE GROUP, 2020-2030
TABLE 52. CHINA ORAL CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 53. AUSTRALIA ORAL CANCER TREATMENT MARKET, BY DRUG TYPE, 2020-2030
TABLE 54. AUSTRALIA ORAL CANCER TREATMENT MARKET, BY AGE GROUP, 2020-2030
TABLE 55. AUSTRALIA ORAL CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 56. INDIA ORAL CANCER TREATMENT MARKET, BY DRUG TYPE, 2020-2030
TABLE 57. INDIA ORAL CANCER TREATMENT MARKET, BY AGE GROUP, 2020-2030
TABLE 58. INDIA ORAL CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 59. SOUTH KOREA ORAL CANCER TREATMENT MARKET, BY DRUG TYPE, 2020-2030
TABLE 60. SOUTH KOREA ORAL CANCER TREATMENT MARKET, BY AGE GROUP, 2020-2030
TABLE 61. SOUTH KOREA ORAL CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 62. REST OF ASIA-PACIFIC ORAL CANCER TREATMENT MARKET, BY DRUG TYPE, 2020-2030
TABLE 63. REST OF ASIA-PACIFIC ORAL CANCER TREATMENT MARKET, BY AGE GROUP, 2020-2030
TABLE 64. REST OF ASIA-PACIFIC ORAL CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 65. ASIA-PACIFIC ORAL CANCER TREATMENT MARKET, BY DRUG TYPE, 2020-2030
TABLE 66. ASIA-PACIFIC ORAL CANCER TREATMENT MARKET, BY AGE GROUP, 2020-2030
TABLE 67. ASIA-PACIFIC ORAL CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 68. LAMEA ORAL CANCER TREATMENT MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 69. BRAZIL ORAL CANCER TREATMENT MARKET, BY DRUG TYPE, 2020-2030
TABLE 70. BRAZIL ORAL CANCER TREATMENT MARKET, BY AGE GROUP, 2020-2030
TABLE 71. BRAZIL ORAL CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 72. SAUDI ARABIA ORAL CANCER TREATMENT MARKET, BY DRUG TYPE, 2020-2030
TABLE 73. SAUDI ARABIA ORAL CANCER TREATMENT MARKET, BY AGE GROUP, 2020-2030
TABLE 74. SAUDI ARABIA ORAL CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 75. SOUTH AFRICA ORAL CANCER TREATMENT MARKET, BY DRUG TYPE, 2020-2030
TABLE 76. SOUTH AFRICA ORAL CANCER TREATMENT MARKET, BY AGE GROUP, 2020-2030
TABLE 77. SOUTH AFRICA ORAL CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 78. REST OF LAMEA ORAL CANCER TREATMENT MARKET, BY DRUG TYPE, 2020-2030
TABLE 79. REST OF LAMEA ORAL CANCER TREATMENT MARKET, BY AGE GROUP, 2020-2030
TABLE 80. REST OF LAMEA ORAL CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 81. LAMEA ORAL CANCER TREATMENT MARKET, BY DRUG TYPE, 2020-2030
TABLE 82. LAMEA ORAL CANCER TREATMENT MARKET, BY AGE GROUP, 2020-2030
TABLE 83. LAMEA ORAL CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030
TABLE 84. BMS: COMPANY SNAPSHOT
TABLE 85. BMS: PRODUCT PORTFOLIO
TABLE 86. CIPLA:COMPANY SNAPSHOT
TABLE 87. CIPLA: OPERATING SEGMENTS
TABLE 88. CIPLA: PRODUCT PORTFOLIO
TABLE 89. LILLY:COMPANY SNAPSHOT
TABLE 90. LILLY: OPERATING SEGMENTS
TABLE 91. LILLY: PRODUCT PORTFOLIO
TABLE 92. ROCHE: COMPANY SNAPSHOT
TABLE 93. ROCHE: OPERATING SEGMENTS
TABLE 94. ROCHE: PRODUCT PORTFOLIO
TABLE 95. FRESENIUS: COMPANY SNAPSHOT
TABLE 96. FRESENIUS: OPERATING SEGMENTS
TABLE 97. FRESENEUS: PRODUCT PORTFOLIO
TABLE 98. INTAS: COMPANY SNAPSHOT
TABLE 99. INTAS: PRODUCT PORTFOLIO
TABLE 100. MERCK: COMPANY SNAPSHOT
TABLE 101. MERCK: OPERATING SEGMENTS
TABLE 102. MERCK: PRODUCT PORTFOLIO
TABLE 103. SANOFI: COMPANY SNAPSHOT
TABLE 104. SANOFI: OPERATING SEGMENTS
TABLE 105. SANOFI: PRODUCT PORTFOLIO
TABLE 106. TEVA: COMPANY SNAPSHOT
TABLE 107. TEVA : OPERATING SEGMENTS
TABLE 108. TEVA: PRODUCT PORTFOLIO
TABLE 109. VIATRIS: COMPANY SNAPSHOT
TABLE 110. VIATRIS : OPERATING SEGMENTS
TABLE 111. VIATRIS: PRODUCT PORTFOLIO
List of Figures
FIGURE 01. ORAL CANCER TREATMENT MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP WINNING STRATEGIES, BY YEAR, 2018-2021
FIGURE 04. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2021 (%)
FIGURE 05. TOP WINNING STRATEGIES, BY COMPANY, 2018-2021
FIGURE 06. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 07. MODERATE BARGAINING POWER OF BUYERS
FIGURE 08. MODERATE THREAT OF SUBSTITUTES
FIGURE 09. MODERATE THREAT OF NEW ENTRANTS
FIGURE 10. MODERATE COMPETITIVE RIVALRY
FIGURE 11. TOP PLAYER POSITIONING, 2020
FIGURE 12. IMPACT ANALYSIS
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF CHEMOTHERAPY ORAL CANCER TREATMENT MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF IMMUNOTHERAPY ORAL CANCER TREATMENT MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF TARGETED THERAPY ORAL CANCER TREATMENT MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF 30-49 ORAL CANCER TREATMENT MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF 50-69ORAL CANCER TREATMENT MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF 70< ORAL CANCER TREATMENT MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 19. COMPARATIVE ANALYSIS OF ORAL CANCER TREATMENT MARKET FOR HOSPITALS PHARMACIES, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 20. COMPARATIVE ANALYSIS OF ORAL CANCER TREATMENT MARKET FOR DRUG STORES & RETAIL PHARMACIES, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 21. COMPARATIVE ANALYSIS OF ORAL CANCER TREATMENT MARKET FOR ONLINE STORES, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 22. BMS: NET SALES, 2018-2020 ($MILLION)
FIGURE 23. BMS: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 24. CIPLA: NET SALES, 2018-2020 ($MILLION)
FIGURE 25. CIPLA: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 26. CIPLA: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 27. LILLY :NET SALES 2018-2020 ($MILLION)
FIGURE 28. LILLY: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 29. ROCHE: NET SALES, 2018-2020 ($MILLION)
FIGURE 30. ROCHE: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 31. ROCHE: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 32. MERCK: NET SALES, 2018-2020 ($MILLION)
FIGURE 33. MERCK REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 34. MERCK REVENUE SHARE BY REGION, 2020 (%)
FIGURE 35. SANOFI: NET SALES, 2018-2020 ($MILLION)
FIGURE 36. SANOFI: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 37. SANOFI: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 38. TEVA: NET SALES, 2018-2020 ($MILLION)
FIGURE 39. TEVA: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 40. TEVA: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 41. VIATRIS: NET SALES, 2018-2020 ($MILLION)
FIGURE 42. VIATRIS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 43. VIATRIS: REVENUE SHARE BY REGION, 2020 (%)
Companies Mentioned
- Bristol-Myers Squibb Company Cipla Inc.
- Eli-Lilly F.
- Hoffmann-La Roche
- Fresenius Kabi AG
- Intas Pharmaceuticals Ltd
- Merck & Co.Inc.
- SanofiTeva Pharmaceuticals Industries Ltd
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
